While at the Harvard Stem Cell Institute, iPierian scientist Dr. John Dimos led a team whose work on iPS cell reprogramming was cited as part of the 2008 "Breakthrough of the Year" by Science magazine.
iPierian’s iPS cell technology now makes it possible to develop pluripotent cell lines from patient populations. The company is applying rigorous criteria, similar to those used in clinical trials, to identify and stratify patients with various forms of major diseases, including spinal muscular atrophy (SMA), ALS, and Parkinson’s disease. This same process will be applied to the company's collaborations with partners in major disease areas such as diabetes, heart disease and Alzheimer’s disease.
iPierian iPS cell platform will open the way to significant and rapid advances in the understanding of the underlying biology and pathology of disease by offering a paradigm-changing technology for investigating and reclassifying major diseases by genotypic and phenotypic subtypes. The company's reprogramming and differentiation technologies make it possible to interrogate disease in disease-specific human model systems, and to develop more effective targeted therapies for patients.